Financial Performance - The company achieved operating revenue of CNY 8,191,000,371.69, an increase of 11.39% compared to the previous year[4] - Net profit attributable to shareholders reached CNY 1,049,085,089.75, representing a growth of 118.11% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,070,385,527.76, up 114.13% from the previous year[4] - Basic earnings per share increased to CNY 0.86, a rise of 120.51% compared to the same period last year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 12,507,539,504.26, reflecting a growth of 4.74% from the beginning of the period[5] - Shareholders' equity attributable to the company increased to CNY 5,850,621,632.10, up 21.01% from the beginning of the period[5] Growth Drivers - The company's earnings growth was driven by increased revenue, improved product profitability, and significant gains in investment and exchange rate income[6][8] - The increase in investment income and exchange rate gains contributed positively to the company's overall performance[8] Operational Challenges - The company effectively managed challenges such as the pandemic, inflation, and rising raw material costs, leading to record-breaking operational performance[8] Investor Advisory - Investors are advised to be cautious as the reported figures are preliminary and unaudited, with final data to be disclosed in the annual report[9]
颖泰生物(833819) - 2022 Q4 - 年度业绩